IDEAS home Printed from https://ideas.repec.org/a/eme/jespps/jes-01-2025-0059.html

Cost-effectiveness and efficacy analysis of biosimilar drugs for lung diseases: a systematic review

Author

Listed:
  • Chiara Alfia Ferrara
  • Paolo Lorenzo Ferrara

Abstract

PurposeCost-effectiveness analysis is an organized method that aids in evaluating and examining the economic aspects and health results linked to different medical procedures. Efficacy analysis considers how effectively a treatment achieves the intended outcome when tested under perfect and controlled conditions. Nowadays, there is a noticeable trend towards using biologics and biosimilar medicines. Specifically, biosimilars are seen as a cheaper alternative to treat long-term health issues traditionally linked with significant medical expenses. A key area for the use of biosimilars is lung diseases, with a fast-growing number of studies on their applications.Design/methodology/approachFollowing Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic review has been conducted. Bibliometric data were collected from the Dimensions database in March 2025. The keywords selected are “biological,” “drugs,” “biosimilar,” “lung,” “diseases,” “cost,” “effectiveness,” “efficacy” and “analysis.” The timespan considered goes from 2004 to 2024.FindingsOf the 2,852 papers retrieved based on our inclusion criteria, only 28 articles published in peer-reviewed journals were considered relevant. Biosimilar drugs are more cost-effective and efficacious than reference drugs, with improvements in asthma control and quality-adjusted life years, though at higher costs in certain cases. No specific conditions alter their economic benefits, except when combined with chemotherapy. Moreover, they are used in various lung diseases, including different types of lung carcinoma and severe allergic asthma. Robust models were used for the cost-effectiveness and efficacy analysis.Originality/valueThe reported outcomes serve as a tool for researchers and policymakers aiming to explore the integration of these new drugs into the healthcare system. From a policy perspective, obtaining a clearer insight into the current landscape enables policymakers to allocate additional funding towards the adoption of cost-effective and efficacious biosimilars in specific areas, improving patient benefit and potentially lowering public healthcare expenditures.

Suggested Citation

  • Chiara Alfia Ferrara & Paolo Lorenzo Ferrara, 2025. "Cost-effectiveness and efficacy analysis of biosimilar drugs for lung diseases: a systematic review," Journal of Economic Studies, Emerald Group Publishing Limited, vol. 52(9), pages 174-192, August.
  • Handle: RePEc:eme:jespps:jes-01-2025-0059
    DOI: 10.1108/JES-01-2025-0059
    as

    Download full text from publisher

    File URL: https://www.emerald.com/jes/article/52/9/174/1275966/Cost-effectiveness-and-efficacy-analysis-of
    Download Restriction: no

    File URL: https://www.emerald.com/jes/article-pdf/52/9/174/10078138/jes-01-2025-0059en.pdf
    Download Restriction: no

    File URL: https://libkey.io/10.1108/JES-01-2025-0059?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eme:jespps:jes-01-2025-0059. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Emerald Support (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.